Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020812 · ClinicalTrials.gov registry record · Phase 1
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01020812: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01020812 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020812, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
To determine the efficacy and toxicity of TACE combined with SBRT
Primary Outcome
Freedom from local progression is defined as the time from start of treatment until the first occurrence of local progression. Local progression is defined as progression in the treated lesion according to the RECIST criteria. Progression outside the treated lesion and/or death will be considered as competing risks. The data was analyzed in a competing risk model with death as a competing risk. The outcome reported is the cumulative incidence at 12 months.
Interventions
- PROCEDURE TACE
- PROCEDURE SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Why NCT01020812 stopped before completion
NCT01020812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which TACE is the first listed.
NCT01020812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01020812 about?
NCT01020812 is a clinical study titled "Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma". To determine the efficacy and toxicity of TACE combined with SBRT
What is the current status of trial NCT01020812?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01020812?
The interventions under investigation include: TACE (PROCEDURE), SBRT (PROCEDURE).
Who is sponsoring clinical trial NCT01020812?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01020812's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia